Linc AB (LINC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Linc AB (LINC) has a cash flow conversion efficiency ratio of -0.001x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.90 Million ≈ $-312.52K USD) by net assets (Skr4.25 Billion ≈ $457.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Linc AB fund operations to measure how many days the company can operate on defensive assets alone.
Linc AB - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Linc AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Linc AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Linc AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brait SE
JSE:BAT
|
-0.002x |
|
Wuhan DDMC Culture Co Ltd
SHG:600136
|
-0.085x |
|
Risuntek Inc
SHE:002981
|
0.022x |
|
KG Mobility Corp.
KO:003620
|
0.049x |
|
Korla Pear
SHG:600506
|
0.136x |
|
Jiangsu Canopus Wisdom Medical Technology Co. Ltd. A
SHE:301290
|
N/A |
|
Apex International Co Ltd
TW:4927
|
0.007x |
|
Anhui Xinbo Aluminum Co Ltd
SHE:003038
|
-0.149x |
Annual Cash Flow Conversion Efficiency for Linc AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Linc AB from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Linc AB (LINC) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr4.43 Billion ≈ $476.85 Million |
Skr4.25 Million ≈ $457.91K |
0.001x | -84.37% |
| 2024-12-31 | Skr4.83 Billion ≈ $519.86 Million |
Skr29.68 Million ≈ $3.19 Million |
0.006x | +126.91% |
| 2023-12-31 | Skr3.53 Billion ≈ $379.78 Million |
Skr-80.57 Million ≈ $-8.67 Million |
-0.023x | +70.88% |
| 2022-12-31 | Skr2.91 Billion ≈ $313.12 Million |
Skr-228.15 Million ≈ $-24.55 Million |
-0.078x | +19.49% |
| 2021-12-31 | Skr3.63 Billion ≈ $390.96 Million |
Skr-353.84 Million ≈ $-38.08 Million |
-0.097x | -1560.96% |
| 2020-12-31 | Skr2.49 Billion ≈ $268.42 Million |
Skr-14.63 Million ≈ $-1.57 Million |
-0.006x | -929.67% |
| 2019-12-31 | Skr1.66 Billion ≈ $178.75 Million |
Skr1.17 Million ≈ $126.34K |
0.001x | +103.83% |
| 2018-12-31 | Skr1.06 Billion ≈ $114.60 Million |
Skr-19.65 Million ≈ $-2.11 Million |
-0.018x | -- |
About Linc AB
Linc AB is a private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies. It prefers to invest in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses. The investments are made in both private and public companies and in research and o… Read more